Market Research Logo

PDE Inhibitors Market, 2016-2026

PDE Inhibitors Market, 2016-2026

The discovery of the second messengers, cAMP and cGMP, in 1958 led to a deeper understanding of the signal transduction processes behind physiological stimulation and response. Later, the identification of phosphodiesterases (PDEs) and the establishment of their role in diseases led to the development of drugs targeting this class of enzymes. PDEs are a complex superfamily of metallophosphohydrolase enzymes that regulate the activity of second messengers. The superfamily consists of 11 different gene families, ranging from PDE1 to PDE11. These enzymes can be differentiated, in terms of their 3D-structure, modes of regulation, cellular localization and sensitivity to inhibitors.

Until 1998, only non-selective PDE inhibitors were available in the market and were primarily indicated for providing symptomatic relief for respiratory diseases, including COPD and asthma. Post the launch of Viagra® in 1998, several selective PDE inhibitors came into the market. At present, there are 13 PDE inhibitors commercially available in different geographies. Due to the involvement of PDEs in multiple cellular processes, inhibitors against these molecular targets are applicable across a diverse range of disease indications. It is worth mentioning that the introduction of PDE inhibitors brought a radical change in the treatment of erectile dysfunction. Consequently, these molecules now occupy a major share in the erectile dysfunction market. In addition, PDE inhibitors are also being developed to address the current unmet need for pharmacological interventions for the treatment of patients suffering from certain neurological diseases, cardiovascular diseases, respiratory diseases and dermatological diseases. Drug candidates targeting schizophrenia, atopic dermatitis, Huntington’s disease, COPD, asthma and Alzheimer’s disease are all in various phases of clinical development.

The success of the marketed PDE inhibitors has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new entrants to actively monetize this growing opportunity.

SCOPE OF THE REPORT
The PDE Inhibitors Market, 2016-2026 study offers a comprehensive analysis of the current landscape of these therapies and an informed opinion on how the field is likely to evolve over the next decade. The market has gained traction during the last few years with many drug candidates designed to address a wide range of diseases. PDE5, with two blockbuster drugs (Viagra® and Cialis®), is one of the most researched PDE inhibitor subtype. In the recent past, another PDE inhibitor subtype, PDE4, has surfaced to address the unmet needs associated with respiratory diseases and dermatological disorders.

Among other things, the report provides the following information:
 A detailed overview of the PDE inhibitors pipeline covering marketed, clinical and preclinical therapies. We have presented information on the respective phases of development, key players involved, PDE inhibitor subtypes, routes of administration and indications being targeted by specific drug candidates.
 Comprehensive profiles highlighting clinical trial details, key clinical results and future market opportunity for the marketed and late stage (phase II and phase III) PDE inhibitors.
 A list of key opinion leaders (KOLs) who have been involved in the discovery and development of PDE inhibitors.
 A discussion on emerging trends and the popularity of PDE inhibitors as observed on social media platforms, such as Twitter, over the last few years.
 A discussion on the potential side effects and the warnings issued by regulatory authorities, indicating areas of improvement for future drug development.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters such as target consumer segments, likely adoption rates and expected pricing, we have provided an estimate of the size of the market in the short-mid-term and long term. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions with experts in the industry. All figures and technical details presented in the report have been sourced and analyzed from publicly available data. All financial figures mentioned in this report are in USD, unless specified otherwise.

EXAMPLE HIGHLIGHTS
1. Around 40 PDE inhibitors are currently in various stages of clinical / preclinical development. PDE4 and PDE5 inhibitors, each occupying over 30% share of the pipeline, have emerged as the most prominent PDE inhibitor subtypes.
2. Several molecules are under development for the treatment of neurological diseases (36%), such as schizophrenia, Alzheimer’s disease and Huntington’s disease; most of these molecules are in early development phases. Other key therapeutic areas include genitourinary diseases (25%) and cardiovascular diseases (11%).
3. Although the market was initially led by large-size pharma players (such as AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer), the current market is characterized by the presence of several small / mid-sized pharma players. Notable examples of small firms and start-ups include (in alphabetical order) BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritechbiopharm, VIVUS, Verona Pharma, and vtv Therapeutics.
4. Several research institutes, companies and organizations have made significant contribution to the overall development of these therapeutics. During our research, we identified over 400 key opinion leaders who have played critical role in the development of PDE inhibitors. Lee Zane (Anacor Pharmaceuticals / Pfizer), Sae Woong Kim (Catholic University Medical College), Dave Singh (Medicines Evaluation Unit) and Min-Gul Kim (Chonbuk National University Hospital) are some of the well-known researchers who have done exemplary work in this field.
5. With the presence of already approved PDE inhibitors such as Viagra® and Cialis®, trends on social media platform have indicated growing trend. In fact, we were able to capture around 2.7 million tweets of relevant keywords over last five years on Twitter.
6. It is important to highlight that the impending patent expiries of currently approved drugs is expected to negatively impact the market’s growth in the short-term. However, it is poised to gain momentum post 2021 after the anticipated approval of a number of late stage product candidates. By 2026, we expect that the overall PDE inhibitors market could be worth over USD 10 billion.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered through secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Other analyst's opinion reports

While the focus has been on forecasting the market over the coming decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the report. It offers a high level view on the evolution of PDE inhibitors market in the mid to long term.

Chapter 3 provides an introduction to PDE enzyme superfamily, including details on the historical timeline of this class of therapeutics and information on different PDE isozymes. The chapter highlights the structure of these enzymes and their role in different cellular activities. It also contains comprehensive information about selective and non-selective PDE inhibitors. In addition, the chapter provides details on the design of PDE inhibitors as well as importance of substrate specificity and potency.

Chapter 4 includes information on over 50 molecules that are either approved or are being evaluated in different stages of development (clinical / preclinical). It features a detailed and comprehensive analysis of the pipeline molecules highlighting the key therapeutic indications, PDE subtypes, phases of development, routes of administration and leading players in the field of PDE inhibitors.

Chapter 5 contains information on various genitourinary and cardiovascular diseases targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of genitourinary and cardiovascular diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results. In addition, the chapter highlights the emerging trends on social media related to PDE inhibitors. It presents an overview of the popularity of the keywords phosphodiesterase inhibitor and PDE inhibitor on Twitter over the last five years.

Chapter 6 contains information on various neurological diseases being targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of neurological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.

Chapter 7 contains information on various dermatological diseases being targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of dermatological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.

Chapter 8 contains information on various respiratory diseases and other key indications targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of respiratory diseases and other key indications. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.

Chapter 9 presents an analysis of the key opinion leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies and the highest phase of development of a clinical trial investigated by them.

Chapter 10 presents a detailed market forecast of PDE inhibitors and a discussion on the overall financial opportunity in this domain. It includes future sales projections for 13 molecules in advanced stages of development. These estimates take into account the target patient population, the existing competition, likely adoption rate and the expected price of each therapy.

Chapter 11 focusses on the various side effects reported by patients treated using these drugs. In addition, the chapter lists the PDE inhibitors that have been terminated during development due to various reasons.

Chapter 12 provides a summary of the overall report. In this chapter, we present a list of key takeaways from the report and our independent opinion on the nature and potential of the PDE inhibitors market. The insights presented in this chapter are based on the research and analysis described in previous chapters.

Chapter 13 contains a collection of interview transcripts of discussions held with some of the key players in the industry.

Chapters 14 and 15 are appendices, which provide tabulated data and a list of companies mentioned in the report, respectively.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the study.
1. Auxilium Pharmaceuticals
2. Aalborg University
3. Academisch Medisch Centrum
4. Actavis
5. AIDS Malignancy Consortium
6. Ajou University Hospital
7. Albany Medical Center
8. Alfred Hospital
9. Alhayah national hospital
10. All India Institute of Medical Sciences
11. Amgen
12. Anacor Pharmaceuticals
13. Anzhen hospital
14. APHP - Hôpital Raymond-Poincaré
15. Aravis Venture
16. ARCH Ventures
17. Army R&R Hospital
18. Asan Medical Center
19. Assiut University
20. Astellas Pharma
21. AstraZeneca
22. Atlanta Gastroenterology Associates
23. Aventis
24. Baxter Healthcare Corp
25. Bayer
26. Baylor Research Institute
27. Beijing University First Hospital
28. BioCrea
29. Boehringer Ingelheim
30. Boston University School of Medicine
31. Bucheon St.Mary's Hospital
32. Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
33. Carinopharm
34. Carlos Haya Hospital Complex
35. Carolinas Healthcare System
36. Catalina Research Institute
37. Catholic University Medical College
38. Cedars-Sinai Medical Center
39. Celerion
40. Celgene
41. Centre for Human Drug Research (the Netherlands)
42. Centre Hospitalier Régional Universitaire de Lille
43. Centre Hospitalier Universitaire de Sherbrooke
44. Chiesi Farmaceutici
45. Children's Healthcare of Atlanta at Egleston
46. Children's Hospital Colorado
47. Children's Hospital of Philadelphia
48. China Medical University Hospital
49. Chonbuk National University Hospital
50. Chong Kun Dang Pharmaceutical
51. Chonnam National University Hospital
52. CHRU de Nîmes - Hôpital Universitaire Carémeau
53. Chulalongkorn University
54. Chungang University Hospital
55. Chungbuk National University Hospital
56. Chungnam National University Hospital
57. CIM Sant Pau - IIB Sant Pau
58. Cincinnati Children’s Hospital Medical Center
59. Clinical Pharmacology of Miami
60. Clinique Beau Soleil
61. Columbia University
62. Comprehensive Cancer Center of Wake Forest University
63. Concert Pharmaceuticals
64. Cristalia
65. CTC Bio
66. Daiichi Sankyo
67. Danish Cancer Society Research Center
68. Danish Headache Center
69. Dart NeuroScience
70. Dong-A Pharmaceutical
71. Dongkook Pharmaceuticals
72. Duke University
73. Eisai
74. elbion
75. Eli Lilly
76. Ewha Womans University Mokdong Hospital
77. FORUM Pharmaceuticals (EnVivo Pharmaceuticals)
78. Freeman Hospital
79. Frontage Clinical Services
80. Fundación Jiménez Díaz
81. Fuwai Hospital
82. Gachon University
83. Georgia Regents University
84. GI Specialists of Georgia
85. Govind Ballabh Pant Hospital
86. GSK
87. Gulf Coast Heart Clinic
88. Hallym University Medical Center
89. Hamad Medical Corporation
90. Hammersmith Medicines Research
91. Hanmi Pharmaceutical
92. HAR de Loja
93. Hatteras Venture Partners
94. Heart Center of Chonnam National University Hospital
95. Helicon Therapeutics
96. Helse Stavanger HF
97. Hoffmann-La Roche
98. Hospira
99. Hospital Ana Nery - Federal University of Bahia
100. Hospital Clinic of Barcelona
101. Hospital Clínico Universitario San Carlos
102. Hospital de Jerez
103. Hospital for State Civil Servants of Sao Paulo
104. Hospital General Universitario Gregorio Marañón
105. Hospital Universitario Doce de Octubre
106. Hospital Universitario La Paz
107. Hospital Universitario La Princesa
108. Hospital Universitario Pedro Ernesto
109. Hospital Universitario Ramón y Cajal
110. Hospital Universitario Reina Sofía
111. Hospital Universitario Virgen Macarena
112. Icahn School of Medicine at Mount Sinai
113. ICM Brain and Spine Insitute
114. Imperial College London
115. Indiana University
116. Inflazyme Pharmaceuticals
117. Inha University Hospital
118. Inje University
119. Innovaderm Research
120. Instituto do Coração (InCor)
121. Intra-Cellular Therapies
122. Ipiranga Hospital
123. Iranian's Ministry of health
124. Jasper Clinic
125. Johns Hopkins University
126. JW Pharmaceuticals
127. Kangdong Sacred Heart Hospital
128. Kerckhoff Heart Center
129. King’s College London
130. Kings County Hospital Center
131. Kobe City Medical Center General Hospital
132. Konkuk University Medical Center
133. Konyang University Hospital
134. Korea University Anam Hospital
135. Korea University Guro Hospital
136. Kosair Pediatric Research Unit
137. Kowa Company
138. Kyorin Pharmaceuticals
139. Kyung Hee University
140. Laval University
141. Le Bonheur Children’s Medical Center
142. Leiden University Medical Center
143. Maastricht University
144. Maimonides Medical Center
145. Mansoura University
146. Maruho
147. Massachusetts General Hospital
148. Mayo Clinic
149. McGill University
150. McGuire VAMC
151. MDS Pharma Services
152. Meda Pharma
153. Medical University of South Carolina
154. Medical University of Vienna
155. Medicines Evaluation Unit
156. Medicinova
157. Medimetriks Pharmaceuticals
158. Menarini
159. Menoufia University
160. Merck
161. Mezzion Pharma
162. Mironid
163. Mitsubishi Tanabe Pharma
164. Montreal Heart Institute
165. Mountain Group Partners
166. Nanjing First Hospital, Nanjing Medical University
167. National Cerebral and Cardiovascular Center
168. National Cheng-Kung University Hospital
169. National Heart, Lung, and Blood Institute (NHLBI)
170. National Institute of Allergy and Infectious Diseases (NIAID)
171. National Institute of Cardiology, Ministry of Health, Brazil
172. National Institute of Neurological Disorders and Stroke (NINDS)
173. National Institute on Aging (NIA)
174. National Jewish Health
175. Nationwide Children's Hospital
176. New York State Psychiatric Institute
177. Northwestern University
178. Nottingham University Hospitals NHS Trust
179. Novartis Venture Funds
180. Nura
181. NuSirt Biopharma
182. Nycomed
183. Omeros Corporation
184. Orexo
185. Otsuka Pharmaceutical
186. Otto Wagner Hospital
187. Palobiofarma
188. PAREXEL International
189. Perinataal Centrum MMC Veldhoven
190. Pfizer
191. Pharmacology Unit - University Hospital of Grenoble
192. Plexera Therapeutics
193. Polytechnic University of Madrid
194. Postgraduate Institute of Medical Education and Research
195. Premier Clinical Research
196. Primary Children’s Medical Center
197. Providence Health & Services
198. Pusan National University Hospital
199. Quality Medical Research
200. Queen Silvia Children´s Hospital
201. Rabin Medical Center, Belinson Hospital
202. Rambam Health Care Campus
203. Respiratory Clinical Trials
204. Rhinopharma
205. Rigshospitalet
206. Riley Hospital
207. Rocky Mountain Research
208. Roivant Sciences
209. Royal Adelaide Hospital
210. Sagene Pharmaceuticals
211. Samsung Medical Center
212. San Diego Sexual Medicine
213. San Giovanni Battista, Hospital University of Turin
214. Sandoz
215. Sanjay Gandhi Postgraduate Institute of Medical Sciences
216. Sanofi
217. Sapienza University of Rome
218. Seoul National University Bundang Hospital
219. Seoul National University College of Medicine
220. Seoul National University Hospital
221. Seoul St. Mary's Hospital
222. Seoul Veterans Hospital
223. Severance Hospital
224. Shahid Sadoughi University of Medical Science
225. Shenyang Northern Hospital
226. SK Chemicals
227. Skane University Hospital
228. SMG-SNU Boramae Medical Center
229. Soon Chun Hyang University
230. Soonchunhyang University Bucheon Hospital
231. Specialties Hospital Complex Juan Ramon Jimenez
232. St George's, University of London
233. Stanford University Medical Center
234. Stanley Medical Research Institute
235. State University of Rio de Janeiro
236. Sterling Research
237. Symyoo
238. Taiho Pharmaceutical
239. Takeda Pharmaceuticals
240. Tameside Hospital NHS Foundation Trust
241. Tehran University of Medical Sciences
242. Temple University Hospital
243. Tetra Discovery partners
244. Teva Pharmaceutical
245. The Catholic University of Korea
246. The Cleveland Clinic
247. The First Affiliated Hospital of Nanjing Medical University
248. The Hospital for Sick Children
249. The Kennedy Krieger Institute
250. The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
251. The University of Texas Health Science Center at San Antonio
252. Transitional Learning Center, University of Texas
253. TriStar Technology Ventures
254. Tritechbiopharm
255. Tulane Medical Center
256. Uniformed Services University of the Health Sciences
257. United Therapeutics
258. University College London
259. University Health Network
260. University Hospital Centre (CHU) de Lyon
261. University Hospital Erlangen
262. University Hospital in Angers
263. University Hospital of Antwerp
264. University Hospital of Puerto Real
265. University Hospital, Angers
266. University Hospitals Leuven
267. University Hospitals Seidman Cancer Center
268. University Magna Graecia of Catanzaro
269. University Medical Center Groningen
270. University Medical Centre Ljubljana
271. University of Adelaide
272. University of Alabama at Birmingham
273. University of Arizona
274. University of British Columbia
275. University of California
276. University of Campinas
277. University of Cincinnati
278. University of Cologne
279. University of Connecticut Health Center
280. University of Copenhagen Herlev Hospital
281. University of Dundee
282. University Of Edinburgh
283. University of Florence
284. University of Gothenburg
285. University of Guadalajara
286. University of Iowa
287. University of Kentucky
288. University of Leicester
289. University of Manitoba
290. University of Miami
291. University of Nebraska
292. University of North Carolina
293. University of Nottingham
294. University of Roma La Sapienza
295. University of Santo Tomas Hospital
296. University of South Florida
297. University of Texas
298. University of Tor Vergata
299. University of Ulsan, Asan Medical Center
300. University of Utah
301. University of Western Ontario
302. Vall Hebron Hospital
303. Vanderbilt University
304. Verona Pharma
305. Viking Global Investors
306. Virginia Commonwealth University
307. Vita-Salute San Raffaele Hospital
308. VIVUS
309. vtv Therapeutics
310. VU Medisch Centrum
311. Wake Forest Baptist Health
312. Warner Chilcott
313. Washington University School of Medicine
314. Wonju College of Medicine
315. Xijing Hospital
316. Yangji Hospital
317. Yangsan Busan University Hospital
318. Yeungnam University
319. Yonsei University
320. Yuebei People's Hospital
321. Zalicus
322. ZNA Middelheim
323. Zydus Cadila


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Phosphodiesterases: A Brief History
3.3. Phosphodiesterases: An Overview
3.3.1. PDE Isozymes: Structure
3.3.2. PDE Isozymes: Function
3.4. PDE Inhibitors
3.4.1. Designing PDE Inhibitors
3.4.2. Substrate Specificity and Potency
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. PDE Inhibitors: A Promising Pipeline
4.3. PDE Inhibitors: Pipeline Analysis
4.3.1. PDE Inhibitors: Distribution by Phase of Development
4.3.2. PDE Inhibitors: Distribution by PDE Subtypes
4.3.3. PDE Inhibitors: Distribution by Therapeutic Areas
4.3.4. PDE Inhibitors: Distribution by Route of Administration
4.3.5. PDE Inhibitors: Distribution by Geography
4.3.6. PDE Inhibitors: Leading Players
5. GENITOURINARY AND CARDIOVASCULAR DISEASES
5.1. Context and Background
5.2. Genitourinary Diseases
5.2.1. Erectile Dysfunction
5.2.1.1. Introduction and Epidemiology
5.2.1.2. Most Prominent PDE Inhibitor Subtypes
5.3.1. Pulmonary Hypertension
5.3.1.1. Introduction and Epidemiology
5.3.1.2. Most Prominent PDE Inhibitor Subtypes
5.4. PDE Inhibitors under Development for Genitourinary Diseases and Cardiovascular Diseases
5.5. Hanmi Pharmaceutical
5.5.1. Company Overview
5.5.2. Financial Performance
5.5.3. PDE Inhibitor Pipeline
5.5.3.1. HGP1207
5.5.3.1.1. Product Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Trials
5.5.3.2. HCP1303
5.5.3.2.1. Product Overview
5.5.3.2.2. Current Status of Development
5.5.3.2.3. Clinical Trials
5.6. PDE Inhibitors: Trends on Social Media
5.7. Trend on Twitter
5.7.1. Most Popular Marketed Drugs
5.7.2. Most Popular PDE Inhibitor Subtypes
5.7.2.1. Most Popular Keywords (Word Cloud Representation)
6. NEUROLOGICAL DISEASES
6.1. Chapter Overview
6.2. Schizophrenia
6.2.1. Introduction and Epidemiology
6.3. Huntington’s Disease
6.3.1. Introduction and Epidemiology
6.3.2. Most Prominent PDE Inhibitor Subtypes
6.4. Alzheimer’s Disease
6.4.1. Introduction and Epidemiology
6.4.2. Most Prominent PDE Inhibitor Subtypes
6.5. PDE Inhibitors under Development for Neurological Diseases
6.6. Boehringer Ingelheim
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. PDE Inhibitor Pipeline
6.6.3.1. BI 409306
6.6.3.1.1. Product Overview
6.6.3.1.2. Current Status of Development
6.6.3.1.3. Clinical Trials
6.6.3.1.4. Key Clinical Trial Results
6.7. Takeda Pharmaceuticals
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. PDE Inhibitor Pipeline
6.7.3.1. TAK-063
6.7.3.1.1. Product Overview
6.7.3.1.2. Current Status of Development
6.7.3.1.3. Clinical Trials
6.7.3.1.4. Key Clinical Trial Results
6.8. Pfizer
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. PDE Inhibitor Pipeline
6.8.3.1. PF-02545920
6.8.3.1.1. Product Overview
6.8.3.1.2. Current Status of Development
6.8.3.1.3. Clinical Trials
6.8.3.1.4. Key clinical Trial Results
6.8.4. Collaborations
6.9. Dart NeuroScience
6.9.1. Company Overview
6.9.2. PDE Inhibitor Pipeline
6.9.2.1. HT-0712 / IPL-455903
6.9.2.1.1. Product Overview
6.9.2.1.2. Current Status of Development
6.9.2.1.3. Clinical Trials
6.9.2.1.4. Key Clinical Trial Results
6.10. Omeros Corporation
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. PDE Inhibitor Pipeline
6.10.3.1. OMS824
6.10.3.1.1. Product Overview
6.10.3.1.2. Current Status of Development
6.10.3.1.3. Clinical Trials
6.10.3.1.4. Key Clinical Trial Results
6.10.4. Collaborations
7. DERMATOLOGICAL DISORDERS
7.1. Chapter Overview
7.2. Atopic Dermatitis
7.2.1. Introduction and Epidemiology
7.2.2. Most Prominent PDE Inhibitor Subtypes
7.3. Psoriasis
7.3.1. Introduction and Epidemiology
7.3.2. Most Prominent PDE Inhibitor Subtypes
7.4. PDE Inhibitors under Development For Dermatology
7.5. Anacor Pharmaceuticals (a part of Pfizer)
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. PDE Inhibitor Pipeline
7.5.3.1. Crisaborole / AN2728
7.5.3.1.1. Product Overview
7.5.3.1.2. Current Status of Development
7.5.3.1.3. Clinical Trials
7.5.3.1.4. Key Clinical Trials
7.6. Otsuka
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. PDE Inhibitor Pipeline
7.6.3.1. OPA-15406 / MM36
7.6.3.1.1. Product Overview
7.6.3.1.2. Current Status of Development
7.6.3.1.3. Clinical Trials
7.6.3.1.4. Key Clinical Trial Results
7.6.4. Collaborations
7.7. Roivant Sciences
7.7.1. Company Overview
7.7.2. PDE Inhibitor Pipeline
7.7.2.1. RVT-501
7.7.2.1.1. Product Overview
7.7.2.1.2. Current Status of Development
7.7.2.1.3. Clinical Trials
7.7.2.1.4. Key Clinical Trial Results
7.7.3. Collaborations
8. RESPIRATORY DISEASES AND OTHER INDICATIONS
8.1. Chapter Overview
8.2. Respiratory Diseases
8.2.1. COPD
8.2.1.1. Introduction and Epidemiology
8.2.1.2. Most Prominent PDE Inhibitor Subtypes
8.2.2. Asthma
8.2.2.1. Introduction and Epidemiology
8.2.2.2. Most Prominent PDE Inhibitor Subtypes
8.2.3. PDE Inhibitors under Development for Respiratory Diseases
8.3. Other Indications
8.3.1. NAFLD / NASH
8.3.1.1. Introduction and Epidemiology
8.3.1.2. Most Prominent PDE Inhibitor Subtypes
8.3.2. PDE Inhibitors under Development for Other Indications
8.4. Chiesi Farmaceutici
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. PDE Inhibitor Pipeline
8.4.3.1. CHF6001
8.4.3.1.1. Product Overview
8.4.3.1.2. Current Status of Development
8.4.3.1.3. Clinical Trials
8.4.3.1.4. Key Clinical Trial Results
8.5. Verona Pharma
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. PDE Inhibitor Pipeline
8.5.3.1. RPL554
8.5.3.1.1. Product Overview
8.5.3.1.2. Current Status of Development
8.5.3.1.3. Clinical Trials
8.5.3.1.4. Key Clinical Trial Results
8.5.4. Collaborations
8.6. NuSirt Biopharma
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. PDE Inhibitor Pipeline
8.6.3.1. NS-0200
8.6.3.1.1. Product Overview
8.6.3.1.2. Current Status of Development
8.6.3.1.3. Clinical Trials
8.6.3.1.4. Key Clinical Trial Results
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. PDE Inhibitors: Prominent Researchers
9.2.2. PDE Inhibitors: Leading Key Opinion Leaders
10. MARKET OPPORTUNITY
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Research Methodology
10.4. Overall PDE Inhibitors Market, 2016-2026
10.4.1. Overall PDE Inhibitors Market: Distribution by Therapeutic Area
10.4.2. Overall PDE Inhibitors Market: Distribution by PDE Subtype
10.5. Daliresp® (AstraZeneca)
10.5.1. Target Patient Population
10.5.2. Sales Forecast
10.6. OTEZLA® (Celgene)
10.6.1. Target Patient Population
10.6.2. Sales Forecast
10.7. Crisaborole (Anacor Pharmaceuticals)
10.7.1. Target Patient Population
10.7.2. Sales Forecast
10.8. OPA-15406 / MM36 (Otsuka Pharmaceutical / Medimetriks Pharmaceuticals)
10.8.1. Target Patient Population
10.8.2. Sales Forecast
10.9. HT-0712 (Dart NeuroScience)
10.9.1. Target Patient Population
10.9.2. Sales Forecast
10.10. RPL554 (Verona Pharma)
10.10.1. Target Patient Population
10.10.2. Sales Forecast
10.11. BI409306 (Boehringer Ingelheim)
10.11.1. Target Patient Population
10.11.2. Sales Forecast
10.12. NS-0200 (NuSirt Biopharma)
10.12.1. Target Patient Population
10.12.2. Sales Forecast
10.13. RVT-501 (Roivant Sciences)
10.13.1. Target Patient Population
10.13.2. Sales Forecast
10.14. CHF6001 (Chiesi Farmaceutici)
10.14.1. Target Patient Population
10.14.2. Sales Forecast
10.15. PF-02545920 (Pfizer)
10.15.1. Target Patient Population
10.15.2. Sales Forecast
10.16. TAK-063 (Takeda Pharmaceutical)
10.16.1. Target Patient Population
10.16.2. Sales Forecast
10.17. OMS824 (Omeros Corporation)
10.17.1. Target Patient Population
10.17.2. Sales Forecast
11. DISCONTINUED MOLECULES AND SIDE EFFECTS
11.1. Chapter Overview
11.2. Discontinued Molecules
11.2.1. Discontinued / Terminated Molecules: Distribution by Phase of Development
11.2.2. Discontinued / Terminated Molecules: Distribution by PDE Subtype
11.3. Precautionary Notes and Common Side Effects
11.3.1. PDE5 Inhibitors
11.3.2. PDE4 Inhibitors
12 CONCLUSION
12.1. The Pipeline Is Dominated By the Presence of PDE4, PDE5 and PDE10 Inhibitors
12.2. Both Big and Small Pharma Players, Keen to Leverage the Broad Spectrum Applicability of This Drug Class, are Actively Involved
12.3. Involvement of Several Prominent Researchers in This Domain and Growing Social Media Chatter Are Indicative of the Popularity of This Drug Class
12.4. Varying Opportunity across Disease Indications is Likely to Translate into a Lucrative Future Growth Potential
13. INTERVIEW TRANSCRIPTS
14. APPENDIX: TABULATED DATA
15. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Schematic Representation of Phosphodiesterases
Figure 3.2 PDE Isozymes: Function
Figure 4.1 PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Figure 4.2 PDE Inhibitors: Distribution by PDE Subtypes
Figure 4.3 PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Figure 4.4 PDE Inhibitors: Distribution by Therapeutic Areas
Figure 4.5 PDE Inhibitors: Distribution by Key Therapeutic Indications
Figure 4.6 PDE Inhibitors: Distribution by PDE Subtype, Therapeutic Area and Phase of Development
Figure 4.7 PDE Inhibitors: Distribution by Route of Administration
Figure 4.8 PDE Inhibitors: Distribution by Geography
Figure 4.9 PDE Inhibitors: Regional Landscape
Figure 4.10 PDE Inhibitors: Leading Players
Figure 5.1 Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Figure 5.2 PDE Inhibitors: Most Popular Marketed Drugs on Twitter, 2010-2015
Figure 5.3 PDE Inhibitors: Most Popular PDE Inhibitor Subtypes on Twitter, 2010-2015
Figure 5.4 PDE Inhibitors: Most Popular Keywords on Twitter, 2010-2015
Figure 6.1 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Figure 6.2 Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Figure 6.3 Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Figure 6.4 Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 6.5 Pfizer: Annual Revenues, 2011 – H1 2016 (USD Billion)
Figure 6.6 Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Figure 6.7 Omeros Corporation: Annual Revenues, 2011- H1 2016 (USD Million)
Figure 6.8 Omeros Corporation: Funding Instances (USD Million)
Figure 7.1 Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Figure 7.2 Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Figure 7.3 Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 8.1 Chiesi Farmaceutici: Annual Revenues, 2010-2015 (EUR Billion)
Figure 8.2 Verona Pharma: Funding Instances (GBP Million)
Figure 8.3 NuSirt Biopharma: Funding Instances (USD Million)
Figure 9.1 PDE Inhibitors: Mapping Prominent Researchers
Figure 9.2 PDE Inhibitors: Leading Key Opinion Leaders
Figure 10.1 Overall PDE Inhibitors Market, 2016-2026, Base Scenario (USD Million)
Figure 10.2 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Figure 10.3 Evolution of PDE Inhibitors Market: Distribution by Therapeutic Area 2016, 2021, 2026 (Base Scenario)
Figure 10.4 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Figure 10.5 Evolution of PDE Inhibitors Market: Distribution by PDE Subtype 2016, 2021, 2026 (Base Scenario)
Figure 10.6 Daliresp Sales Forecast, Base Scenario (USD Million)
Figure 10.7 OTEZLA Sales Forecast, Base Scenario (USD Million)
Figure 10.8 Crisaborole Sales Forecast, Base Scenario (USD Million)
Figure 10.9 OPA-15406 Sales Forecast, Base Scenario (USD Million)
Figure 10.10 HT-0712 Sales Forecast, Base Scenario (USD Million)
Figure 10.11 RPL554 Sales Forecast, Base Scenario (USD Million)
Figure 10.12 BI409306 Sales Forecast, Base Scenario (USD Million)
Figure 10.13 NS-0200 Sales Forecast, Base Scenario (USD Million)
Figure 10.14 RVT-501 Sales Forecast, Base Scenario (USD Million)
Figure 10.15 CHF6001 Sales Forecast, Base Scenario (USD Million)
Figure 10.16 PF-02545920 Sales Forecast, Base Scenario (USD Million)
Figure 10.17 TAK-063 Sales Forecast, Base Scenario (USD Million)
Figure 10.18 OMS824 Sales Forecast, Base Scenario (USD Million)
Figure 11.1 Discontinued / Terminated Molecules: Distribution by Phase of Termination
Figure 11.2 Discontinued / Terminated Molecules: Distribution by PDE Subtype
Figure 12.1 PDE Inhibitors: Developer Landscape
Figure 12.2 PDE Inhibitors: Key Indications
Figure 12.3 PDE Inhibitors: Market Opportunity across Different Disease Indications
Figure 12.4 PDE Inhibitors Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2026 (USD Billion)
LIST OF TABLES
Table 3.1 PDE Superfamily
Table 3.2 Non-selective PDE Inhibitors
Table 4.1 PDE Inhibitors: Marketed and Developmental Pipeline
Table 4.2 PDE Inhibitors: Unknown Status
Table 5.1 PDE Inhibitors: Genitourinary and Cardiovascular Diseases
Table 5.2 Hanmi Pharmaceuticals: PDE Inhibitor Pipeline
Table 5.3 HGP1207: Current Status of Development
Table 5.4 HGP1207: Clinical Trials
Table 5.5 HCP1303: Current Status of Development
Table 5.6 HCP1303: Clinical Trials
Table 6.1 PDE Inhibitors Pipeline: Neurological Diseases
Table 6.2 Boehringer Ingelheim: PDE Inhibitor Pipeline
Table 6.3 BI 409306: Current Status of Development
Table 6.4 BI 409306: Clinical Trials
Table 6.5 BI 409306: Clinical Trial Results (NCT01505894)
Table 6.6 BI 409306: Clinical Trial Results (NCT01611311)
Table 6.7 Takeda Pharmaceuticals: PDE Inhibitor Pipeline
Table 6.8 TAK-063: Current Status of Development
Table 6.9 TAK-063: Clinical Trials
Table 6.10 Pfizer: PDE Inhibitor Pipeline
Table 6.11 PF-02545920: Current Status of Development
Table 6.12 PF-02545920: Clinical Trials
Table 6.13 Dart NeuroScience: PDE Inhibitor Pipeline
Table 6.14 HT-0712: Current Status of Development
Table 6.15 HT-0712: Clinical Trials
Table 6.16 Omeros Corporation: PDE Inhibitor Pipeline
Table 6.17 OMS824: Current Status of Development
Table 6.18 OMS824: Clinical Trials
Table 7.1 PDE Inhibitors Pipeline: Dermatological Disorders
Table 7.2 Anacor Pharmaceuticals: PDE Inhibitors Pipeline
Table 7.3 Crisaborole: Current Status of Development
Table 7.4 Crisaborole: Clinical Trials
Table 7.5 Crisaborole: Phase III Clinical Trial Results
Table 7.6 Otsuka: PDE Inhibitor Pipeline
Table 7.7 OPA-15406: Current Status of Development
Table 7.8 OPA-15406: Clinical Trials
Table 7.9 Roivant Sciences: PDE Inhibitor Pipeline
Table 7.10 RVT-501: Current Status of Development
Table 7.11 RVT-501: Clinical Trials
Table 8.1 PDE Inhibitors Pipeline: Respiratory Diseases
Table 8.2 PDE Inhibitors: Marketed and Pipeline (Other Indications)
Table 8.3 Chiesi Farmaceutici: PDE Inhibitor Pipeline
Table 8.4 CHF6001: Current Status of Development
Table 8.5 CHF6001: Clinical Trials
Table 8.6 Verona Pharma: PDE Inhibitor Pipeline
Table 8.7 RLP554: Current Status of Development
Table 8.8 RLP554: Clinical Trials
Table 8.9 NuSirt: PDE Inhibitor Pipeline
Table 8.10 NS-0200: Current Status of Development
Table 8.11 NS-0200: Clinical Trials
Table 9.1 KOLs: Phase IV Clinical Trials
Table 9.2 KOLs: Phase III Clinical Trials
Table 9.3 KOLs: Phase II Clinical Trials
Table 9.4 KOLs: Phase I Clinical Trials
Table 9.5 KOLs: Other Clinical Trials
Table 10.1 Marketed / Late Phase PDE Inhibitors: Actual / Estimated Launch Year
Table 10.2 Daliresp: Target Patient Population
Table 10.3 OTEZLA: Target Patient Population
Table 10.4 Crisaborole: Target Patient Population
Table 10.5 OPA-15406: Target Patient Population
Table 10.6 HT-0712: Target Patient Population
Table 10.7 RPL554: Target Patient Population
Table 10.8 BI409306: Target Patient Population
Table 10.9 NS-0200: Target Patient Population
Table 10.10 RVT-501: Target Patient Population
Table 10.11 CHF6001: Target Patient Population
Table 10.12 PF-02545920: Target Patient Population
Table 10.13 TAK-063: Target Patient Population
Table 10.14 OMS824: Target Patient Population
Table 11.1 PDE Inhibitors: Discontinued / Terminated Molecules,
Table 14.1 PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Table 14.2 PDE Inhibitors: Distribution by PDE Subtypes
Table 14.3 PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Table 14.4 PDE Inhibitors: Distribution by Therapeutic Areas
Table 14.5 PDE Inhibitors: Distribution by Key Therapeutic Indications
Table 14.6 PDE Inhibitors: Distribution by Route of Administration
Table 14.7 PDE Inhibitors: Distribution by Geography
Table 14.8 PDE Inhibitors: Leading Players
Table 14.9 Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Table 14.10 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Table 14.11 Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Table 14.12 Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Table 14.13 Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.14 Pfizer: Annual Revenues, 2011 – Q1 2016 (USD Billion)
Table 14.15 Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Table 14.16 Omeros Corporation: Annual Revenue, 2011- H1 2016 (USD Million)
Table 14.17 Omeros Corporation: Funding Instances (USD Million)
Table 14.18 Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Table 14.19 Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Table 14.20 Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.21 Chiesi Farmaceutici: Annual Revenue, 2010-2015 (EUR Billion)
Table 14.22 Verona Pharma: Funding Instances (GBP Million)
Table 14.23 NuSirt Biopharma: Funding Instances (USD Million)
Table 14.24 Overall PDE Inhibitors Market, 2016-2026, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.25 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Table 14.26 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Table 14.27 Daliresp Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.28 OTEZLA Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.29 Crisaborole Sales Forecast, Base Scenario (USD Million)
Table 14.30 OPA-15406 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.31 HT-0712 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.32 RPL554 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.33 BI409306 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.34 NS-0200 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.35 RVT-501 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.36 CHF6001 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.37 PF-02545920 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.38 TAK-063 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.39 OMS824 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.40 Discontinued / Terminated Molecules: Distribution by Phase of Termination
Table 14.41 Discontinued / Terminated Molecules: Distribution by PDE Subtype

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report